At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based CFO’ operating in the Therapeutics space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Lee Kalowski
Chief Financial Officer of Bicycle Therapeutics
Lee has served as chief financial officer at Tokai since September 2014. Prior to joining Tokai, he served as a vice president in global biotechnology equity research at Credit Suisse. In this role, Lee served as a senior research analyst covering the biotechnology industry, including numerous companies globally in the prostate cancer therapeutic area. Prior to Credit Suisse, Lee worked at Johnson & Johnson in mergers & acquisitions in the pharmaceutical group, where he was involved in the analysis and execution of several completed transactions, and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group. Lee holds a B.A., Phi Beta Kappa, in biology and economics, from Union College and an M.B.A. in finance and health care management from the Wharton School, University of Pennsylvania.
Follow Lee Kalowski:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Shaun Holt
CFO of Berkeley Lights
Shaun joined Berkeley Lights in November 2015 and was appointed Chief Financial Officer in March 2016. Prior to becoming CFO, Shaun was Vice President of Finance. Prior to joining Berkeley Lights, Shaun spent 7 ½ years at Illumina, Inc. heading up various aspects of their Finance organization. His roles included Sr. Director, Global Head of R&D and Business Unit Finance, EMEA Head of Finance, Accounting and Facilities, and Commercial FP&A. He earned a B.S. in Finance from California State University, Stanislaus.
Follow Shaun Holt:
About Berkeley Lights: Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Brian Piper
Chief Financial Officer of Prelude Therapeutics
Brian Piper joined Medgenics as VP, Finance and Investor Relations in April 2014. Prior to joining Medgenics, Mr. Piper served as Senior Director, Strategic Investment Group (SIG), for Shire Pharmaceuticals, LLC from 2010 to 2013, as well as several different finance and business development roles with Shire over the past 13 years. Mr. Piper began his affiliation with Shire in 2002 as Director of Finance for Shire’s North American Development group in Rockville, MD. In 2004 he established Shire’s first US Investor Relations group, based out of Philadelphia. After three years running US Investor Relations, Mr. Piper transitioned to an alliance management role and spent two years overseas in Dublin, Ireland helping establish geographic expansion strategies. Prior to joining Shire, Mr. Piper held strategic planning roles for Celera Genomics, was Controller for a start-up Contract Research Organization, and worked as a program planner and financial analyst for Otsuka Pharmaceuticals, Inc. Mr. Piper received a B.B.A. from the University of Notre Dame and an M.B.A. from the Robert H. Smith School of Business at the University of Maryland.
Follow Brian Piper:
About Aevi Genomic Medicine, Prelude Therapeutics, Scorpion Therapeutics: Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and resistance.
Robert Bermon
Chief Financial Officer of Invo HealthCare Holdings
Robert Bermon, CPA brings more than 20 years of senior financial management experience to the Invo Family of Companies and currently serves as the organizations chief Financial Officer. As CFO, Bob oversees the shared services support team which includes accounting, finance and human resources. Prior to Bob joining the team in 2016, he was the Executive Vice President and Chief Financial Officer at Solomon Edwards. Through streamlined business operations, financial controls and processes that drove growth, efficiency and bottom-line profit, Bob was instrumental in building the infrastructure that promoted the company’s growth. Bob’s career started with accounting firm Grant Thornton. Bob holds a Bachelor of Arts in Accounting from Temple University and is a Certified Pubic Account (CPA).
Follow Robert Bermon:
About Invo HealthCare Holdings: Founded in 1993 by Patrick McClain, an Occupational Therapist, and Mary McClain, an Educator.
Terry Colip
Founder, Managing Member & CFO of Cell Point
Terry Colip, the Founder of Cell>Point, was a founding member of the firm and has provided his expertise from its inception. Mr. Colip has 26 years of expertise in investment banking and venture capital in the healthcare industry. Prior to founding Cell>Point, Mr. Colip worked as a healthcare consultant for Coopers & Lybrand in New York. He provided equity and investment banking services for roughly $2 billion in healthcare transactions at Underwood Neuhaus & Co., Boettcher & Co., and American Health Capital, Inc. Mr. Colip was also a founding partner in Chewton Glen Energy L.L.C. This company built two electric power plants in Illinois. Many media outlets, including Fox Business Network, Fox News, NBC News Denver, ABC News Denver, CBS News Denver, and National Public Radio, have highlighted Mr. Colip. Mr. Colip earned a B.S.I.E. in 1979 from the University of Wisconsin’s College of Engineering and an M.P.A. in finance and healthcare administration from New York University in 1981. Mr. Colip donates his time and resources to charities and organizations that focus on healthcare and disability outreach.
Follow Terry Colip:
About Cell Point: Cell Point is a biotechnology company developing universal molecular imaging agents and intra-nuclear metallic therapeutics.
Georgia Erbez
Chief Financial Officer of Harpoon Therapeutics
Georgia Erbez currently works as the Chief Financial Officer for Harpoon Therapeutics. She previously worked at Artelo Biosciences, Inc. as the Member Board Of Directors.
Follow Georgia Erbez:
About Harpoon Therapeutics: Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Brett Kaplan
Chief Financial Officer of Prevail Therapeutics
Brett Kaplan is our Chief Financial Officer. Prior to Prevail, he was Managing Director at Evercore, where he spent eight years concentrating on biopharma M&A and equity financings. Prior to Evercore, Brett was an Equity Research Analyst at Cowen, where he covered large cap pharmaceuticals. Earlier in his career, he held senior positions at Cubist and Lilly focused on corporate and business development. Brett holds an MBBCh and an MBA from the University of Witwatersrand in South Africa.
Follow Brett Kaplan:
About Prevail Therapeutics: Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Adam Cutler
Chief Financial Officer of Molecular Templates
Adam Cutler has served as Molecular Templates’ Chief Financial Officer since November 2017.Prior to joining Molecular Templates, he was Senior Vice President of Corporate Affairs at Arbutus Biopharma from 2015-2017, where his responsibilities included investor relations, business development, and corporate finance. From 2012-2015, he was a Managing Director for The Trout Group and Trout Capital, where he executed financings and advised life science companies on investor relations, capital raising, and business development. From 2000-2011, he was a biotechnology equity research analyst at Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Merrill Lynch. He also worked in healthcare consulting at The Frankel Group and Ernst & Young. He currently serves on the Board of Directors for Inmed Pharmaceuticals and Navidea Biopharmaceuticals. He received his B.A. in Economics from Brandeis University.
Follow Adam Cutler:
About Molecular Templates: Molecular Templates develops novel therapeutic compounds for cancer.
David Sachs
Chief Financial Officer of ImmunityBio
In July 2019, ImmunityBio hired David Sachs as its Chief Financial Officer. As a finance, private equity, venture capital, and investment banking executive, he has over two decades of operational, development, and investing expertise. Sachs was formerly the CFO of various NantWorks companies, including NantHealth and Integrity Healthcare. He was also a principal and executive of NantCapital, where he sat on the investment committee. Sachs formerly worked as an investment banker for Bank of America Merrill Lynch and in senior operational roles at Abraxis BioScience and Celgene. He is now on the boards of Mox Networks, LLC, Packetfabric, Inc., and the Chan Soon-Shiong Medical Center at Windber. Sachs earned his MBA in Finance and Strategy from UCLA Anderson School of Management, as well as his BA in Economics from the University of California, Los Angeles.
Follow David Sachs:
About ImmunityBio, NantHealth: ImmunityBio is an offshoot of Soon-Shiong’s NantWorks conglomerate, developing molecular-level cell-based treatments for diseases.
David Neafus
CFO of Santi Therapeutics
David Neafus is the CFO of Santi Therapeutics.
Follow David Neafus:
About Be the Partner, Galenea, IlluminOss Medical, Intrinsic Therapeutics, PanGenX, Santi Therapeutics, Triton Resources, Wingu: Santi Therapeutics is a pharmaceutical company that focuses on the research and development of small molecule therapeutics.
Gary Martell
CFO of Skyhawk Therapeutics
Follow Gary Martell:
About Blu Homes, Skyhawk Therapeutics: Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
James Hinrichs
Executive Vice President and Chief Financial Officer of Alere
James (“Jim”) Hinrichs joined Alere in April 2015 as Executive Vice President and Chief Financial Officer, with global responsibility for Finance, Accounting, Procurement, IT and Shared Services. Prior to his appointment as CFO of Alere, Jim Hinrichs was CFO at CareFusion Corp., a global medical technology corporation, since 2010. He held this position through the completion of Becton Dickinson’s acquisition of CareFusion in March 2015. Prior to this role, Hinrichs served as SVP of Global Customer Support and, before that, Corporate Controller of CareFusion. Previously, he was Executive Vice president and Controller of Cardinal Health, CFO of Cardinal Health’s Clinical and Medical Products segment and CFO of Cardinal Health’s Healthcare Supply Chain Services segment.. He joined Cardinal Health in February 2004, following 12 years of finance and marketing roles at Merck & Co. and two years as the CFO of SangStat Medical Corporation.
Follow James Hinrichs:
About Alere: Alere provides diagnostics and health management solutions for infectious, heart and cancer-related diseases and drug addicts.
Jaime Bartushak
CFO of Citius Pharmaceuticals
Follow Jaime Bartushak:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Linda C. Bain
CFO of Codiak Biosciences
Linda C. Bain, CPA, has served as our vice president of finance and business operations since October 2011 and as our treasurer since March 2013. Previously, she served as vice president of corporate finance at Genzyme from September 2008 to September 2011, at Fidelity Investments from September 2007 to September 2008 and a number of positions at AstraZeneca from May 2000 to September 2007. She received her B.S. from the University of the Orange Free State in South Africa.
Follow Linda C. Bain:
About Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Bryan Giraudo
Chief Financial Officer & COO of Gossamer Bio
Mr. Giraudo is the Chief Financial Officer of Gossamer Bio. Previously, he was Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Bryan was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Bryan received his B.A. from Georgetown University.
Follow Bryan Giraudo:
About Gossamer Bio: Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
Jim Berend
Chief Financial Officer & Executive Vice President of USMD
Jim Berend serves as chief financial officer and executive vice president of USMD Holdings. In his position, Jim oversees all of USMD’s finance functions and activities. Jim has more than 35 years of experience in healthcare finance, having served as a CFO, consultant, auditor and partner at international accounting and consulting firms. He has extensive experience in all aspects of healthcare accounting and finance across the care continuum. Previously, Jim served as CFO and executive vice president of a company operating surgical hospitals in Texas. He was responsible for finance and accounting, centralized billing office, materials management and hospital financial operations.Jim received his Bachelor of Business Administration, with highest honors, from The University of Texas in Austin. He is a licensed CPA in Texas.
Follow Jim Berend:
About USMD: USMD Holdings develops, operates and manages entities that deliver diagnostic, therapeutic and hospital-based health care to patients.
Michael Banks
CFO of Kineta
Michael Banks serves as the Chief Financial Officer of Kineta.
Follow Michael Banks:
About Kineta: Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.
Jeffrey B. McGroarty
Chief Financial Officer of Annovis Bio
Follow Jeffrey B. McGroarty:
About Annovis Bio: Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
Reid McCarthy
Consulting Chief Financial Officer of Annovis Bio
Follow Reid McCarthy:
About Annovis Bio: Annovis Bio develops novel treatments for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
Douglas Larson
Group Chief Financial Officer of Beyond Air
Douglas Larson is the Group Chief Financial Officer at Beyond Air.
Follow Douglas Larson:
About Beyond Air: Beyond Air is a biotechnology company focused on the development of drugs for the treatment of lung infections.
Kimi Iguchi
CFO of SAGE Therapeutics
Kimi Iguchi joined SAGE Therapeutics in March 2013 as Chief Financial Officer with more than 15 years of progressive experience managing finance, accounting, operations and human resources in emerging life science companies. Prior to joining SAGE, Ms. Iguchi has led the organizational development of strategic business plans, portfolio management, deal structure, fund raising, financial planning, and operations infrastructure design and growth. She has held positions at Warp Drive Bio, LLC, Santhera Pharmaceuticals, Cyberkinetics, Millennium Pharmaceuticals and Biogen, Inc. She began her career at PricewaterhouseCoopers LLP, Boston. Ms. Iguchi holds a B.A. in chemistry from Drew University, received her MBA from Northeastern University, and earned her CPA in Massachusetts.
Follow Kimi Iguchi:
About SAGE Therapeutics: SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Jeff Poulton
Chief Financial Officer of Alnylam Pharmaceuticals
Follow Jeff Poulton:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Paul Kim
Chief Financial Officer of Fulgent Therapeutics
Paul Kim has served as Fulgent Chief Financial Officer since 2016. Prior to his service for us, Mr. Kim served as Chief Financial Officer of Cogent, a publicly traded biometric identification services and product company from 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, or JNI, a publicly traded storage area network technology company, from 2002 until 2003, as Vice President, Finance and Corporate Controller at JNI from 1999 to 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from 1998 until 1999. From 1996 to 1998, Mr. Kim was the Corporate Controller for Interlink Computer Sciences, Inc., a publicly traded enterprise software company. From 1990 to 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.
Follow Paul Kim:
About Fulgent Therapeutics: Fulgent Therapeutics, LLC is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics.
Dane Saglio
CFO of Helomics
Dane Saglio serves as Chief Financial Officer of Helomics®. Formerly, Mr. Saglio was the CFO of RegeneRx Biopharmaceuticals, Inc; SuperNova Diagnostics; New Generation Biofuels; EntreMed Biopharmaceuticals; and held senior financial positions with Sterling Software, Inc. and Public Communication Associates. Mr. Saglio also has extensive public and private company experience along with a wide range of corporate finance and strategic transactions experience. Dane earned his B.S. in business administration from the University of Maryland and is a licensed CPA (inactive).
Follow Dane Saglio:
About Helomics, RegeneRx: Helomics provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services.
Fred Driscoll
Chief Financial Officer of Flexion Therapeutics
Fred Driscoll has more than 20 years of experience in financial management of life sciences companies, most recently as the Chief Financial Officer at Flexion Therapeutics, Inc., where he spearheaded an initial public offering in 2014. Prior to joining Flexion, he served as Chief Financial Officer at Novavax, Inc. from 2009 to 2013. From 2008 to 2009, Fred Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. Prior to serving as Chief Executive Officer of Genelabs he was the Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Fred Driscoll served as Chief Executive Officer at OXiGENE, Inc., where he also served as Chairman of the Board and Audit Committee Chair. He was also a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016. Fred Driscoll earned a B.S. in accounting and finance from Bentley University. He is a member of the board of directors of Cellectar Biosciences, Inc., MEI Pharma, Inc. and NantKwest, Inc.
Follow Fred Driscoll:
About Flexion Therapeutics: Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.
Melissa Epperly
Chief Financial Officer of Psioxus Therapeutics
Melissa Epperly is a senior finance executive with deep healthcare experience. Prior to joining PsiOxus, Melissa was CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology pharmaceutical company based in Princeton, NJ. At R-Pharm US she led corporate and business development, leading the integration of the asset purchase of Ixempra ® (a metastatic breast cancer treatment) from Bristol-Myers Squibb. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund, where she drove operational excellence in their portfolio companies to facilitate and enable exponential growth. Prior to that she was a Vice President at Goldman Sachs in equity research where she helped develop, build, and commercialize a novel, global equity research product for long-term investing, GS SUSTAIN, in the US and Europe. Before joining Goldman Sachs she was a management consultant with Bain & Company in New York and London, focused on international and US based pharmaceutical clients and private equity. She previously worked at Morgan Stanley in New York in healthcare investment banking and banking management, enabling pharmaceutical and biotech companies to accelerate growth through strategic MandA and capital raising. Melissa holds an MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.
Follow Melissa Epperly:
About Psioxus Therapeutics: Psioxus Therapeutics is a cancer gene therapy company delivers medicines of value to patients with cancer.
James M. O’Brien
Chief Financial Officer of Cognition Therapeutics
James M. O’Brien is the Chief Financial Officer at Cognition Therapeutics.
Follow James M. O’Brien:
About Cognition Therapeutics: Cognition Therapeutics develops new therapeutics to treat patients suffering from Alzheimer’s disease and other neurodegenerative disorders.
Hunter Smith
Chief Financial Officer of Rhythm Pharmaceuticals
Hunter Smith is the Chief Financial Officer at Rhythm Pharmaceuticals.
Follow Hunter Smith:
About Rhythm Pharmaceuticals: Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Jeffrey Poulton
Chief Financial Officer of Shire
Jeffrey “Jeff” brings to the Board his financial, commercial and strategic acumen. Since joining Shire in 2003 he has held leadership positions in finance supporting the Neuroscience, Gastrointestinal and Rare Diseases business units as well as the positions of Interim Chief Financial Officer and Head of Investor Relations. In addition, Jeff oversaw the operations of the Rare Diseases business unit in North America, Latin America and Asia Pacific, as well as leading the integration of the legacy-Viropharma rare disease products into the Shire portfolio. Prior to joining Shire, Jeff spent time at Cinergy Corp. and PPG Industries in a variety of corporate finance and business development roles, in addition to serving as a commissioned officer in the U.S. Navy. He received a Bachelor of Arts in Economics from Duke University and a Master of Business Administration in Finance from the Kelly School of Business at Indiana University.
Follow Jeffrey Poulton:
About Shire: Shire biotechnology company that focuses on serving people with rare diseases.
David Pool
Chief Financial Officer of Ocunexus Therapeutics
Mr. Pool joined CoDa Therapeutics as Chief Financial Officer in July 2008. He has over 20 years investment banking and venture capital experience including privatization transactions, leasing, securitizations, venture capital raising and initial public offerings. Mr. Pool has raised over $50M for early stage Biotech companies. Mr. Pool’s responsibilities include all financial and accounting functions as well as driving CoDa’s fund raising process and business development activities. Prior to CoDa, Mr. Pool was Protemix Corporation’s Chief Operating and Financial Officer for 5 years. Mr. Pool holds a Bachelor of Commerce in accounting and business administration from the University of Canterbury and is a member of the Institute of Chartered Accountants of New Zealand.
Follow David Pool:
About Inflammx Therapeutics, Ocunexus Therapeutics: Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology.
Frank Ruffo
Co-Founder, Chief Financial Officer of Aclaris Therapeutics
Frank Ruffo co-founded Aclaris and has served as Chief Financial Officer since its inception in 2012. He is a senior financial executive with more than 20 years of biotech and specialty pharmaceutical management expertise in early stage through fully commercial operations. From 2014 to 2015, Frank served part time as a financial consultant at Ralexar Therapeutics, Inc. (formerly known as Alexar Therapeutics Inc.), a specialty dermatology company. Frank also served part time as the Chief Financial Officer of VenatoRx Pharmaceuticals Inc., a pharmaceutical company, from 2011 to 2014 and the Chief Financial Officer of BioLeap, Inc. from 2010 to 2013. Prior to joining Aclaris, Frank co-founded and served as Chief Financial Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan in 2011. Prior to joining Vicept Therapeutics, from 1996 to 2008 he served as the Vice President, Finance and Controller of CollaGenex Pharmaceuticals, Inc. Frank is a certified public accountant in Pennsylvania (inactive since 2008). He received his Bachelor of Science in business administration with a major in accounting from La Salle University.
Follow Frank Ruffo:
About Aclaris Therapeutics, Vicept Therapeutics: Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
David McClung
Vice President of Finance & Accounting(Chief Financial Officer) of BioCardia
David McClung has served as our Vice President of Finance since 2016 and has been with the company since September 2013. Mr. McClung has more than 20 years of finance and accounting experience in publicly and privately financed organizations, including startup enterprises, middle-market businesses and large public companies. For the last ten years he has held leadership roles in emerging businesses, primarily life science ventures, most recently as the Controller for Sonitus Medical Inc. and NextWave Pharmaceuticals, Inc. He spent his early career in public accounting, beginning with KPMG LLP, after which he gained broad financial and operational experience directing the North American audit group for The Clorox Company and serving as Director of Internal Audit for Matson Navigation, Inc. Mr. McClung earned a Bachelor of Arts degree in Accounting from Georgia State University, graduating with honors. He is an actively licensed CPA and member of the AICPA and the California Society of CPAs.
Follow David McClung:
About BioCardia: BioCardia is a clinical-stage regenerative medicine company.
McDavid Stilwell
Chief Financial Officer of Coherus Biosciences
McDavid Stilwell is the Chief Financial Officer at Coherus BioSciences.
Follow McDavid Stilwell:
About Coherus Biosciences: Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.
Hodges Mauri
Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Catalyst Biosciences
Ms. Hodges joined Targacept in August 2000 and currently serves as Vice President, Finance and Administration, Chief Financial Officer and Treasurer. Ms. Hodges was previously Vice President, Human Resources and Corporate Systems and served as Controller for over thirteen years. Ms. Hodges has over eighteen years of biotech and information technology industry experience in the areas of finance, audit, strategy, corporate governance, facilities management, and public company preparedness and oversight. She began her career working in public accounting with Deloitte, Haskins and Sells, and as an entrepreneur, owned and operated a certified public accounting firm for over eight years. She is a member of the World at Work organization, American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants. Ms. Hodges received a B.S. in Business Administration and Accounting from Virginia Polytechnic Institute and State University.
Follow Hodges Mauri:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Hodges Mauri
Vice President, Finance and Administration, Chief Financial Officer and Treasurer of Catalyst Biosciences
Ms. Hodges joined Targacept in August 2000 and currently serves as Vice President, Finance and Administration, Chief Financial Officer and Treasurer. Ms. Hodges was previously Vice President, Human Resources and Corporate Systems and served as Controller for over thirteen years. Ms. Hodges has over eighteen years of biotech and information technology industry experience in the areas of finance, audit, strategy, corporate governance, facilities management, and public company preparedness and oversight. She began her career working in public accounting with Deloitte, Haskins and Sells, and as an entrepreneur, owned and operated a certified public accounting firm for over eight years. She is a member of the World at Work organization, American Institute of Certified Public Accountants and the North Carolina Association of Certified Public Accountants. Ms. Hodges received a B.S. in Business Administration and Accounting from Virginia Polytechnic Institute and State University.
Follow Hodges Mauri:
About Catalyst Biosciences: Catalyst Biosciences is a drug R&D company creating catalytic biopharmaceutical products based on engineered human proteases.
Jeffrey Fryer
Co-Founder & CFO of Rallybio
Jeff Fryer is the Co-Founder & Chief Financial Officer at Rallybio.
Follow Jeffrey Fryer:
About Rallybio: Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.
Dan T. Bessey
CFO of Thermogenesis
Follow Dan T. Bessey:
About Thermogenesis: Thermogenesis, a health care company, focuses in development of automated technologies for cell-based therapeutics and bioprocessing.
Ian C. Sanderson
CFO of Nimbus Therapeutics
Follow Ian C. Sanderson:
About Boston Pharmaceuticals, Nimbus Therapeutics: Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Daniella Beckman
CFO of Tango Therapeutics
Daniella Beckman has served as the senior vice president, chief financial officer and treasurer of Idenix since March 2012 and the vice president, chief financial officer and treasurer since June 2011. Daniella Beckman served as the interim chief financial officer and treasurer of Idenix from October 2010 to June 2011 and as the corporate controller of Idenix from March 2008 to October 2010. Before joining Idenix, Daniella Beckman held positions at Coley Pharmaceutical Group, most recently as corporate controller. Prior to Coley, Daniella Beckman also held positions at Biogen Idec from September 2004 through March 2006 as well as PricewaterhouseCoopers from September 2000 through September 2004. Daniella Beckman holds a B.A. from Boston University and is also a Certified Public Accountant (CPA).
Follow Daniella Beckman:
About Tango Therapeutics: Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Thomas R. Staab
SVP & CFO of BioCryst Pharmaceuticals
Tom Staab joined the BioCryst Leadership Team in July 2011, bringing his skill and experience regarding the financial stewardship of publically-traded companies, development and commercialization of pharmaceutical products and raising capital through strategic partnerships, equity and debt financings. Mr. Staab most recently served as Executive Vice President, CFO and Treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held the senior financial positions of Acting CFO and Treasurer at Triangle Pharmaceuticals, Inc. through its $480 million acquisition by Gilead Sciences, Inc. Additionally, Mr. Staab spent eight years working for PricewaterhouseCoopers LLP providing audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Tom currently serves on the Board of the NC Biosciences Organization (NCBIO) and is a member of its Audit Committee, and he has received several awards for his contribution and leadership to other organizations. He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.
Follow Thomas R. Staab:
About BioCryst Pharmaceuticals: BioCryst has over 80 employees spread across their two locations in Birmingham, Alabama and Durham, North Carolina.
Scott Gorton
CFO of Apton Biosystems
Follow Scott Gorton:
About Apton Biosystems, Cloudleaf, Precursor Energetics: Apton Biosystems develops a high-throughput and low-cost sequencing platform that revolutionizes the availability of genetic analysis.
Jason Leverone
Chief Financial Officer of Viridian Therapeutics
Jason A. Leverone, C.P.A., is miRagen’s Chief Financial Officer. In this capacity, he oversees the company’s financial, accounting, and operations functions. Prior to joining miRagen, Mr. Leverone was Senior Director of Finance and Controller for Replidyne, Inc., a publicly-traded biotechnology company. At Replidyne, he played an important role in completing the company’s initial public offering and executing its strategic sale to Cardiovascular Systems, Inc. Prior to joining Replidyne, Mr. Leverone was the Corporate Controller for CreekPath System, Inc., an international software development company. He commenced his professional career with the accounting firm of Ernst and Young LLP and served as an Audit Manager for Arthur Andersen LLP. Mr. Leverone is a Certified Public Accountant and holds a Bachelor of Science in Business Administration from Bryant University in Smithfield, Rhode Island.
Follow Jason Leverone:
About Viridian Therapeutics: Viridian Therapeutics discovers and develops innovative microRNA-targeting therapies to improve human health.
Michael Broughton
CFO of Cambium Medical Technologies
Michael Broughton is CFO at Cambium Medical Technologies.
Follow Michael Broughton:
About Cambium Medical Technologies: CMT focuses on the development and commercialization of regenerative therapies derived from novel processed human platelets.
Chuck Abdalian
CFO of Checkmate Pharmaceuticals
Follow Chuck Abdalian:
About Checkmate Pharmaceuticals: Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Charles Garner
Chief Financial Officer of Lung Therapeutics
Chuck Garner joined Lung Therapeutics in 2018 as Chief Financial Officer. Mr. Garner brings over 20 years of investment banking, corporate finance, business development and financial operational experience to Lung Therapeutics. Most recently, Mr. Garner was a life sciences industry consultant to private and public life sciences companies, providing financial and advisory services. Prior to this, Mr. Garner was Chief Financial Officer and Chief Business Officer for Recro Pharma, Inc., successfully leading the company’s initial public offering and acquisition of select assets from Alkermes, plc. Mr. Garner began his professional career as a certified public accountant with PricewaterhouseCoopers and, while an investment banker for Deutsche Bank AG, raised or advised on over $8 billion of financial and advisory transactions for healthcare clients. Mr. Garner received his Bachelors of Business Administration, high distinction, with a concentration in accounting and finance from the University of Michigan.
Follow Charles Garner:
About Lung Therapeutics: Lung Therapeutics provides innovative treatments for underserved, life-threatening lung conditions.
Martin P. Galvan
CFO of Lannett Company
Mr. Martin P. Galvan, CPA, is Chief Financial Officer, Vice President – Finance, Treasurer of Lannett Company Inc. Most recently, he was Chief Financial Officer of CardioNet, Inc., a medical technology and service company. From 2001 to 2007, Mr. Galvan was employed by Viasys Healthcare Inc., a healthcare technology company that was acquired by Cardinal Health, Inc. in June 2007. Prior to the acquisition, he served as Executive Vice President, Chief Financial Officer and Director Investor Relations. From 1999 to 2001, Mr. Galvan served as Chief Financial Officer of Rodel, Inc., a precision surface technologies company in the semiconductor industry. From 1979 to 1998, Mr. Galvan held several positions with Rhone-Poulenc Rorer Inc., a pharmaceutical company, including Vice President, Finance — The Americas; President & General Manager, RPR Mexico & Central America; Vice President, Finance, Europe/Asia Pacific; and Chief Financial Officer, United Kingdom & Ireland. Mr. Galvan began his career with the international accounting firm Ernst & Young LLP. He earned a Bachelor of Arts degree in economics from Rutgers University and is a member of the American Institute of Certified Public Accountants.
Follow Martin P. Galvan:
About Lannett Company: Lannett develops, manufactures, and distributes generic prescription pharmaceutical products in tablet.
Scott Giacobello
Chief Financial Officer of GW Pharmaceuticals
Scott Giacobello brings 25 years of finance and operational experience to GW Pharmaceuticals.He is an accomplished executive who most recently and until its acquisition by Allergan, Inc. in late 2016, served as Chief Financial Officer for Chase Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, Inc., most recently serving as Vice President of Finance for Global Research & Development. While at Allergan, he also served as Vice President of Corporate Finance and Vice President of Internal Audit & Compliance. Scott’s previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. Mr. Giacobello holds a bachelor’s degree in business administration from the University of Notre Dame and is a Certified Public Accountant.
Follow Scott Giacobello:
About GW Pharmaceuticals: GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics.
John Borgeson
Chief Financial Officer of ALX Oncology
John Borgeson is our Chief Financial Officer and has served in this position since June 2014. Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. Previously Borgeson was a Vice President of Finance at Pfizer and a member of Pfizer’s Global Financial Leadership Team. Borgeson’s roles at Pfizer included CFO for Pfizer’s biotherapeutics division and corporate tax executive with responsibility for US and Europe. Under Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies. Borgeson has more recently led finance for a variety of private biotech companies, including Labrys Biologics, which was acquired by Teva Pharmaceuticals for $825 million. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant. He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
Follow John Borgeson:
About ALX Oncology, Kodiak Sciences: ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Kelly Deck
Chief Financial Officer of Inhibrx
Kelly Devine Deck is the Chief Financial Officer at InhibRx.
Follow Kelly Deck:
About Inhibrx: Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.
William Harris
CFO of EnGeneIC
Follow William Harris:
About EnGeneIC: EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
Anthony M. Rimac
Chief Financial Officer of Cognoa
Follow Anthony M. Rimac:
About Cognoa: Cognoa is a behavioral health company focused on improving the lives and outcomes of children and families living with behavioral conditions
Christopher P. Schnittker
SVP and Chief Financial Officer of Echo Therapeutics
Mr. Schnittker brings a broad base of financial experience to Echo Therapeutics. Most recently, he served as Vice President – Administration, Corporate Secretary and Chief Accounting Officer of Soligenix, Inc., a publicly-traded biotechnology company. Prior to that, Mr. Schnittker served as the Senior Vice President and CFO for VioQuest Pharmaceuticals Inc., Micromet Inc., CytogenCorporation, and Genaera Corporation, all publicly-traded biotechnology companies. Mr. Schnittker has also held prior financial management positions at GSI Commerce, Rhône-Poulenc Rorer (now part of Sanofi-Aventis), and PricewaterhouseCoopers. He received his B.A. degree in economics and business from Lafayette College and is a certified public accountant licensed in the State of New Jersey.
Follow Christopher P. Schnittker:
About Echo Therapeutics: Echo Therapeutics develops the Symphony tCGM System, a novel, non-invasive (needle-free) glucose monitoring system for diabetes patients.
Stephen Hall
Executive Vice President, Chief Financial Officer of BG Medicine
Mr. Hall joined BG Medicine from Stemline Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company ,where he held the position of Vice President Finance, Treasurer, Principal Financial and Chief Accounting Officer and assisted in financings in excess of $100m. Prior to Stemline, Mr. Hall served as Chief Financial Officer at both life science and medical device companies, including Orthocon, Inc., Helicos BioSciences Corporation, TriPath Imaging, Inc., and Colorado MEDtech, Inc. Mr. Hall, a certified public accountant, began his professional career with Peat, Marwick, Mitchell & Co., in Chicago, IL. In addition to his experience as an operating CFO, he spent nearly 10 years in commercial banking. He received his AB degree from Harvard College and MBA from Stanford University Graduate School of Business.
Follow Stephen Hall:
About BG Medicine: BG Medicine is a life sciences company developing biomarker-based diagnostic tests for the cardiovascular sectors.
Anurag Goel
CFO, Board Of Directors & Investor of Celltheon
Anurag Goel is the CFO/Business Development/Board Of Directors at Celltheon.
Follow Anurag Goel:
About Afferent Technologies, Celltheon: Celltheon is a cell line development and expression technologies company.
Ken Mace
Chief Financial Officer of Alzheon
Follow Ken Mace:
About Alzheon: Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
David Haffner
EVP , Chief Operating Officer & Chief Financial Officer of ALung Technologies
David Haffner is the EVP , Chief Operating Officer & Chief Financial Officer at ALung Technologies, Inc.
Follow David Haffner:
About ALung Technologies: ALung Technologies develops medical gas exchange devices for the treatment of acute and chronic respiratory disorders.
Steve Krognes
CFO of Denali Therapeutics
Mr. Steve Krognes serves as Senior Vice President, Regional Head of Finance and IT and Chief Financial Officer of Pharma North America at Genentech, Inc. Mr. Krognes joined Roche in January 2004 as global head of Mergers and Acquisitions. He served as Head of Corporate Finance-Corporate Development of Roche Holding AG. In this role, he led Roche’s internal Mergers and Acquisitions group and was responsible for all Roche transactions worldwide. Prior to joining Roche Holding AG, Mr. Krognes worked as a venture capitalist in Scandinavia, as a mergers and acquisitions investment banker with Goldman Sachs and Danske Bank, and as a management consultant with McKinsey & Co. He has been a Director of California Healthcare Institute since August 2010. He is a second lieutenant in the Royal Norwegian Air Force. Mr. Krognes holds a Master’s in Business Administration from the Harvard Business School and a Bachelor’s in Economics from the Wharton School at the University of Pennsylvania.
Follow Steve Krognes:
About California Healthcare Institute, Denali Therapeutics: Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Kathleen Larrimer Beckmann
CFO of Tioma Therapeutics
Ms. Beckmann has been a project management and business development consultant for sixteen years. She has expertise in finance, operations, marketing, strategic planning, and training, as well as experience in the healthcare sector. Prior to consulting, Ms. Beckmann worked in product management and financial analysis in the consumer banking industry. She received her M.B.A. from the Stanford Graduate School of Business in 1991 and her B.A. (Honors) from Princeton University in 1985.
Follow Kathleen Larrimer Beckmann:
About Euclises Pharmaceuticals, Tioma Therapeutics: Tioma Therapeutics is a venture-stage biopharmaceutical company.
Howard Liang
President and CFO of Tessera Therapeutics
Follow Howard Liang:
About Tessera Therapeutics: Tessera Therapeutics is an early-stage life sciences company.
Lynn Blake
CFO of SynerFuse
Lynn is the Chief Financial Officer of SynerFuse and Executive Vice President of State Street Global Advisors (SSGA) and CIO of Global Equity Beta Solutions. In this capacity, she oversees a team of 70 portfolio managers globally, and more than 1,600 portfolios with assets in excess of $1.4 trillion across all equity index and smart beta strategies. She also oversees SSGA’s Corporate Governance and Global Proxy Voting as well as the Company Stock Group which manages fiduciary transactions and company stock investments, including company stock ownership and 401K plans. In addition, she is a member of the SSGA Fiduciary Committee, the Investment Committee, and the IT Steering Committee. Lynn also serves as a member of SSGA’s Executive Management Group. Prior to her current role, Lynn was head of non-US markets of passive equities, responsible for overseeing the management of all non-US equity index strategies, as well as serving as portfolio manager for several equity index portfolios. She joined SSGA in 1987. Lynn has a Master of Business Administration in finance from Northeastern University, and a Bachelor of Science from the Boston College Carroll School of Management. She earned the Chartered Financial Analyst (CFA) designation and is a member of the CFA Institute and the Boston Security Analyst Society. She also serves on various index advisory boards and committees.
Follow Lynn Blake:
About State Street Global Advisors, SynerFuse: SynerFuse is a provider of traditional spine implants intended to offer long-term pain management without the use of addictive opioids
Eric Shaff
CFO of Seres Therapeutics
Eric Shaff has over 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. He serves as the executive vice president and chief financial officer of [Seres Therapeutics](https://www.crunchbase.com/organization/seres-health#/entity), a therapeutics company engaged in the R&D of drugs for the treatment of microbiome diseases. Previously, Shaff was vice president of corporate finance at Momenta Pharmaceuticals, where he helped manage Momenta Pharmaceutical’s accounting, finance, planning, and procurement functions as well as contributing to Momenta Pharmaceutical’s investor relations efforts. Prior to joining Momenta Pharmaceuticals, he was the vice president of finance at Genzyme’s Rare Genetic Disease Division. Shaff held several positions in business unit finance, corporate finance, and corporate development at Genzyme. Before joining Genzyme, he worked in corporate finance at Pfizer and worked in investment banking for Broadview International. Shaff obtained his bachelor’s degree in political science and economics from the University of Pennsylvania and his MBA in finance from the Johnson Graduate School of Management at Cornell University.
Follow Eric Shaff:
About Seres Therapeutics: Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products.
Don Munoz
Chief Financial Officer of NuCana BioMed
Don Munoz is the Chief Financial Officer at NuCana BioMed.
Follow Don Munoz:
About NuCana BioMed: NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Paul Brannelly
Chief Financial Officer of Ribon Therapeutics
Follow Paul Brannelly:
About Ribon Therapeutics: Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Daniel Gutschenritter
Chief Financial Officer of MedMark Treatment Centers
Dan Gutschenritter is EVP & Chief Financial Officer of BayMark Health Services,. Dan joined MedMark Services as Chief Financial Officer in October 2012. He has over twenty years of experience in the fields of finance and operations management. Priorto MedMark, Dan had been the Chief Financial Officer for Medical Clinic of North Texas, P.A. (MCNT). Other roles include serving as the Chief Financial Officer and Administrative Officer of Partners Imaging LP, a company which developed and managed imaging joint ventures with physician groups. Dan has extensive experience working in both public and private equity backed organizations having raised in excess of $350 million in new capital over the course of his career. Dan received his MBA from the Fuqua School of Business at Duke University and completed his undergraduate work at the University of Wisconsin.
Follow Daniel Gutschenritter:
About BayMark Health Services, MedMark Treatment Centers: MedMark Treatment Centers is a pharmacy company that provides specialized pharmacy care to patients with unique or chronic medication.
Joy Nassif
Chief Financial Officer of ANIZOME
Ms. Nassif has over 20 years’ experience in financial and executive management in the healthcare, diagnostic testing, and pharmaceutical industries. Her career has included demonstrated ability to maximize return on investment through aggressive working capital and operating expense management. Additionally, she has experience in building and operationalizing start-up corporations. She currently serves as the Chief Operating Officer of Diversigen, Inc. where she leads all aspects of the company’s sales, marketing, and operational efforts. In the years prior to joining Diversigen, Ms. Nassif held leadership positions at Quest Diagnostics as Vice President of Clinical Trials, and Vice President of Anatomic Pathology. During her tenure at Quest Diagnostics, she developed the strategy for the pharmaceutical division, led the transformation of the international clinical trials business from loss making to profit, and launched the first profitable product in cytology for the company. She obtained a Green Belt in Six Sigma Quality. Ms. Nassif held the positions of Chief Financial Officer and Chief Operating Officer of Franklin Heath, Inc. (A Corning Company). She was responsible for all aspects of operations and administration for this start-up healthcare company. Additionally, Ms. Nassif was director of Finance for Covance, Inc. working in its Phase II-III contract research organization. There, she had international responsibilities for pricing, contracts, revenue recognition, and budgeting. Ms. Nassif graduated summa cum laude from Kean University with a BS in Accounting. She is a Certified Public Accountant. In addition to her corporate positions, she has served on the Board of Advisors for several non-profit groups and organizations.
Follow Joy Nassif:
About ANIZOME: ANIZOME is a microbiome platform company dedicated to improving animal health by translating cutting-edge research.
David A. Frank
Chief Financial Officer of AquaBounty Technologies
Follow David A. Frank:
About AquaBounty Technologies: AquaBounty Technologies is a biotechnology company that focuses on improving productivity in commercial aquaculture.
Daniel Clark
Interim Chief Financial Officer of Kiromic Biopharma
On September 30, 2021, the Board of Directors of the Company appointed Dan Clark as interim Chief Financial Officer, effective September 30, 2021. Mr. Clark joined the Company in February 2020 and served as the Company’s Corporate Controller until September 2021, when he was promoted to Vice President – Finance Operations prior to his appointment as interim Chief Financial Officer. Before joining the Company, Mr. Clark was a Manager with The Siegfried Group, a national accounting services firm, from June 2018 to February 2020. Prior to his employment with The Siegfried Group, Mr. Clark served as Senior Consultant – Office of the CFO Solutions for FTI Consulting, a global financial consulting firm, from January 2017 to May 2018. Prior to that, Mr. Clark was Senior Associate – Audit at KPMG US, a member of Big Four global accounting firm KPMG, from August 2011 to June 2015.
Follow Daniel Clark:
About Kiromic Biopharma: Kiromic develops biomarker- and small molecule-based diagnostic and therapeutic programs for solid tumors and hematologic malignancies.
Donald J. Griffith
Chief Financial Officer of Outlook Therapeutics
Follow Donald J. Griffith:
About Outlook Therapeutics: Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics.
Lawrence A. Kenyon
Chief Financial Officer of Outlook Therapeutics
Lawrence A. Kenyon is the Chief Financial Officer of Outlook Therapeutics.
Follow Lawrence A. Kenyon:
About Outlook Therapeutics: Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics.
Ola Soderquist
CFO/Controller & Co-founder of Oxygen Therapy
Follow Ola Soderquist:
About Oxygen Therapy: Oxygen Therapy is a biopharma company that develops anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.
Jeff Wills
President, Chief Financial Officer & Co-Founder of OptionOne Pharmacy
Jeff has been redefining the standard of care in home health for over 20 years. He founded Canadian Valley Medical Solution (CVMS) in 1991 as a provider of medical equipment and infusion services. The company grew to become the largest independent home healthcare company in the state of Oklahoma and was acquired in 2006 by a Fortune 50 company in the medical industry. CVMS enjoyed a pristine reputation as a result of placing a strong emphasis on patient needs thereby ensuring the continuum of care. Just as was the case with CVMS, Jeff began OptionOne based on the perception that the Midwest was in great need of a patient-focused, progressive healthcare provider. Jeff has been a driving force in developing the homecare industry through the assumption of numerous leadership roles in homecare organizations, such as the MED Group, the American Association of Homecare and Home Medical Equipment and Respiratory Therapy Advisory Council. In addition, Jeff has acted as a business consultant to business owners all over the country. He also actively serves his community through Life Church and by membership on numerous local boards, for both profit and non-profit organizations. Jeff holds a Bachelor’s degree in Accounting and Computer Science from Southwestern Oklahoma State University.
Follow Jeff Wills:
About OptionOne Pharmacy: OptionOne is a specialty pharmacy providing home and alternate-site infusion therapies.
Paul A. Stone
Chief Financial Officer & General Counsel of IDEAYA Biosciences
Stone Paul A. joined IDEAYA Biosciences as Chief Financial Officer, General Counsel in 2018.Paul A. Stone, J.D. joined 5AM Ventures in July 2009 as General Counsel and Chief Operating Officer. In addition to his legal and operational responsibilities, he serves as a Board Observer at Kinestral, Rennovia and Wildcat. Mr. Stone has held managerial and operating roles at several private and public biopharmaceutical companies. Most recently he was General Counsel and Senior VP Intellectual Property at Ethos Pharmaceuticals. Previously he was Senior VP, General Counsel, and Chief Patent Counsel at Ilypsa (acquired by Amgen). Prior to Ilypsa, he was VP, Chief Patent Counsel for Symyx (IPO in 1999). Mr. Stone received his J.D. from the University of Wisconsin Law School in 1995 and practiced as a Patent Attorney at Senniger, Powers, Leavitt & Roedel. He taught patent law, trade secrets law and licensing as an adjunct professor at the University of Missouri and Santa Clara University.
Follow Paul A. Stone:
About 5AM Ventures, IDEAYA Biosciences: IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality
John Trainer
Chief Financial Officer of NexImmune
John Trainer is the Chief Financial Officer at NexImmune.
Follow John Trainer:
About NexImmune: NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.
Kurt Dinkelacker
Executive Vice President & Chief Financial Officer of Aptuit LLC
Follow Kurt Dinkelacker:
About Aptuit LLC: Aptuit LLC is a contract research organization.
Lynne Rollins
CFO of Gene Sciences, Inc.
Lynne has over 25 years of experience in accounting and finance, and has worked with numerous startup companies. At Gene Sciences, she is responsible for finance and all contract negotiations.
Follow Lynne Rollins:
About Gene Sciences, Inc.: Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.
Misty Gruber
CFO and Co-Founder of SIWA Therapeutics
Misty Gruber is the Chief Financial and Scientific Affairs Officer/General Counsel and a member of the Board of SIWA. Prior to co-founding SIWA, Ms. Gruber served as Co-Chair of the biotechnology section of law the Dykema Gossett PLLC law firm, with a focus in corporate governance, mergers and acquisitions and securities law matters, including private and public securities offerings. Over her almost thirty years as an attorney, she represented issuers, investors, underwriters and venture capital companies. She also was licensed as a CPA in Arizona for several years. Ms. Gruber was a co-founder of Arryx, Inc. and a co-founder and initial member of the Board of Hyseq, Inc. (after going public, it was subsequently merged into another public company). Ms. Gruber is a member of the Visiting Committee of the Oriental Institute at the University of Chicago and the Madison Council of the Library of Congress. In addition to a J.D., she has an M.S. in biology.
Follow Misty Gruber:
About SIWA Therapeutics: SIWA Therapeutics is a biotechnology company that has a monoclonal antibody that targets and destroys senescent cells.
Zack McNealy
CFO of Inception Sciences
Zack McNealy joined Ventus Therapeutics as CFO in 2019.Zack McNealy is the Vice President, Finance responsible for Versant’s domestic and international management company entities. Zack also works extensively with a number of Versant’s biotech portfolio companies on their international structuring and operational setup. Zack joined Versant after spending seven years at Biotie Therapies (formerly Synosia Therapeutics) where he was Vice President, Finance supporting the U.S. and Swiss operations of the company. Prior to Biotie, Zack spent ten years at Johnson & Johnson as Plant Controller, Finance Manager and Financial Analyst. Zack received an MBA from the Wharton School, University of Pennsylvania and a BS in finance and accounting from Miami University (Ohio).
Follow Zack McNealy:
About Inception Sciences, Ventus Therapeutics: Inception Sciences creates therapies with transformative potential to address diseases and disorders with significant unmet need.
Jim Herrmann
CFO / COO of Cour Pharmaceuticals Development
Jim is a financial and operations executive with over 25 years experience spanning finance, product development, manufacturing and regulatory, in both diagnostics and therapeutics. Jim co-founded Tolera Therapeutics, where he worked with CEO John Puisis to raise $20 million and bring its MAb therapy from pre-clinical to a Phase 3 Special Protocol Assessment. Prior to this, Jim served as CFO for Third Wave Technologies (NASDAQ: TWTI), where he oversaw long-range and annual planning, company-wide systems and infrastructure development, operational management as well as quality system oversight. Jim oversaw the company’s first FDA 510k filing for a molecular diagnostic and the launch of its multiplexing diagnostic platform. Jim is a graduate of the University of Notre Dame and the University of Chicago (MBA).
Follow Jim Herrmann:
About Cour Pharmaceuticals Development: Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Kendall Stever
Chief Financial Officer of Cerevast Therapeutics
Kendall joined Zonar in 2011 and serves as the Company’s Chief Financial Officer. Kendall brings 25 years of financial experience and leadership to Zonar, with a background working with high growth companies. Previously, Kendall was CFO of Verathon Medical, Inc., a leading designer, developer and manufacturer of proprietary medical devices. Verathon marketed its products globally with operations in 7 countries and was acquired by Roper Industries in 2009. Kendall was also Corporate Controller for Immunex Corporation, a premier developer of biopharmaceutical technology. He joined Immunex in 1990 and held various financial management positions during the company’s growth from a 200 person research company to a fully integrated research, manufacturing, and sales organization employing more than 2,000 employees with annual sales exceeding $1 billion. Kendall’s background also includes working with publicly and privately-held companies, as both an executive and consultant, in the areas of corporate compliance, projections and valuations, corporate financing, and accounting operations. He started his career in 1987 as an auditor with the public accounting firm of Deloitte and Touche. He is a CPA and holds a B.A. in business administration from the University of Washington.
Follow Kendall Stever:
About Cerevast Therapeutics, Zonar Systems: Cerevast Therapeutics is a medical technology company developing treatments for acute ischemic stroke and other vascular disorders.
John Nepute
CFO of Cascade Prodrug
John Nepute is Cascade Prodrug’s Chief Financial Officer. He comes to Cascade Prodrug with significant experience in financial and business development roles. Most notably, Mr. Nepute was the President of Monaco Coach Corporation where he led investor relations, M&A, operations, and ultimately grew the company from sales of $17 million and 75 employees to the peak of $1.4 billion in sales and 6800 employees.
Follow John Nepute:
About Cascade Prodrug: Cascade Prodrug, a revitalized pharmaceutical company, develops targeted prodrug therapies for hyper-proliferative diseases.
Prathyusha Duraibabu
CFO of Sangamo Therapeutics
Prathyusha Duraibabu is the CFO at Sangamo Therapeutics.
Follow Prathyusha Duraibabu:
About Sangamo Therapeutics: Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.
William Washecka
CFO of Prestwick Pharmaceuticals
William Washecka is the chief financial officer of [Prestwick Pharmaceuticals](https://www.crunchbase.com/organization/prestwick-pharmaceuticals-inc#/entity), a company that develops and markets therapeutic pharmaceutical drugs for chronic central nervous systems diseases. He was previously a senior partner of Ernst & Young.
Follow William Washecka:
About Ernst & Young, Prestwick Pharmaceuticals: Prestwick Pharmaceuticals develops and markets therapeutic pharmaceutical drugs for chronic central nervous systems diseases.
Roger Jensen
Chief Financial Officer of DxNA
President of Centennial Capital Corporation, a financial advisory firm specializing in Mergers and Acquisitions, Corporate Finance and Reorganization, and Strategic Growth Planning. He has over 25 years senior management experience in a variety of industries including Life Science and has been engaged with DxNA since 2012. From 1997-2001 he served as Executive Vice President for Apogent Technologies where he had the lead role in creating and managing Apogent’s $200 million Microbiology Group. In this and other corporate capacities he has developed and successfully introduced numerous diagnostic products into both the clinical and research markets. He has earned an MBA and CPA having started his career with KPMG (formerly Peat, Marwick) in their business advisory practice. He brings to DxNA significant business, management and financial expertise.
Follow Roger Jensen:
About DxNA: DxNA develops integrated systems and tests for rapid real-time PCR molecular diagnostics.
James Maples
Chief Financial Officer & Director of Administration of DxNA
Mr. James Maples has operated as Chief Financial Officer for DxNA LLC and other preceding related companies. He has lectured at Dixie State Collage on Entrepreneurship and at Utah State University has taught upper division Marketing. Mr. Maples has had a wide and varied career in commercial real estate as a broker and commercial real-estate development. He has been an owner and manager of several small businesses and has served as General Manager of a technical plastics manufacturing company and a Hologram manufacturing company. He received his B,S, in Production Management and his M.B.A. from Utah State University.
Follow James Maples:
About DxNA: DxNA develops integrated systems and tests for rapid real-time PCR molecular diagnostics.
Jordan Corey
Chief Financial Officer of Cero Therapeutics
Jordan Corey is the Chief Financial Officer at CERo Therapeutics.
Follow Jordan Corey:
About Cero Therapeutics: CERo Therapeutics, Inc. is a new cellular immunotherapy company.
Michael Kaswan
Chief Financial Officer of Cognoptix
Michael Kaswan is the Chief Financial Officer at Cognoptix.
Follow Michael Kaswan:
About Cognoptix, Dune Medical Devices: Cognoptix develops non-invasive eye tests for the early diagnosis of alzheimer disease.
John Swoboda
Chief Financial Officer of Measurement Analytics
Mr. Swoboda has, over the past decade, served as an officer and director for several start-ups including glucose measurement and patient monitoring IP companies like Measurement Analytics. Mr. Swoboda is a certified Public Accountant with nearly 40 years of experience. He has owned his own practice, John F. Swoboda, CPA since 1974, serving a wide variety of clients in New Mexico and other states for several decades. Upon completing his Bachelor of Science in Business from Fort Hayes State College(1971), and his Master of Science in Accounting from Oklahoma State University(1972), he worked predominantly in auditing and taxation with Elmer Fox & Company, a national CPA firm, before opening his own public accounting firm.
Follow John Swoboda:
About Measurement Analytics: Measurement Analytics, Inc. (MAI) is an intellectual property company that has acquired technology utilization rights.
John Swoboda
Chief Financial Officer of Measurement Analytics
Mr. Swoboda has, over the past decade, served as an officer and director for several start-ups including glucose measurement and patient monitoring IP companies like Measurement Analytics. Mr. Swoboda is a certified Public Accountant with nearly 40 years of experience. He has owned his own practice, John F. Swoboda, CPA since 1974, serving a wide variety of clients in New Mexico and other states for several decades. Upon completing his Bachelor of Science in Business from Fort Hayes State College(1971), and his Master of Science in Accounting from Oklahoma State University(1972), he worked predominantly in auditing and taxation with Elmer Fox & Company, a national CPA firm, before opening his own public accounting firm.
Follow John Swoboda:
About Measurement Analytics: Measurement Analytics, Inc. (MAI) is an intellectual property company that has acquired technology utilization rights.
Gordon Galloway
CFO of Vali Nanomedical
Gordon Galloway received his MBA from the UCLA Anderson School of Management and his BSBA from the UC Berkeley Haas School of Business. Of nine years working in finance, he spent three in banking and two at Stryker Corporation, a Fortune 500 manufacturer and technology leader in the medical device industry. At Stryker, he helped support the acquisition of two entrepreneurial startups in order to commercialize cutting-edge health care technology around the world. He has worked alongside Dr. Gray on a variety of projects for over a decade, and became Vali’s CFO in 2014.
Follow Gordon Galloway:
About Vali Nanomedical: Vali is a biotechnology company founded in 2013.
Dwight Foster
CFO of TeloRegen Inc.
Follow Dwight Foster:
About TeloRegen Inc.: TeloRegen Inc. (TeloRegen) is a biotech company with a published pending patent for a practical Telomere Therapy in regenerative medicine.